MAPT and Alzheimer disease: The related driving forces that regulate the glial–lymphatic system, affecting its fluid exchange, may also affect the removal of harmful substances such as Aβ and tau protein (Iliff et al., 2012; Kriegel et al., 2018), thereby improving the prognosis of AD and making the glial–lymphatic system an important part of the potential therapeutic target for AD.